| Literature DB >> 33984824 |
Jiawen Deng1, Fangwen Zhou2, Wenteng Hou2, Zachary Silver3, Chi Yi Wong2, Oswin Chang2, Anastasia Drakos2, Qi Kang Zuo4, Emma Huang2.
Abstract
The COVID-19 pandemic and its accompanying infection control measures introduced significant disruptions to the routines of many higher education students around the world. It also deprived them of in-person counselling services and social support. These changes have put students at a greater risk of developing mental illness. The objective of this review is to assess the prevalence of depressive symptoms, anxiety symptoms and sleep disturbances in higher education students during the pandemic. A systematic search of English and Chinese databases was conducted current to January 1st, 2021. The quality of included studies was evaluated using a modified Newcastle-Ottawa scale. Prevalence of depressive symptoms, anxiety symptoms and sleep disturbances were pooled using random-effects meta-analysis. Eighty-nine studies (n=1,441,828) were included. The pooled prevalence of depressive symptoms, anxiety symptoms, and sleep disturbances was 34%, 32% and 33%, respectively. The prevalence values differ based on geographical regions, diagnostic criteria, education level, undergraduate year of study, financial situation, living arrangements and gender. Overall, the prevalence of depressive symptoms and anxiety symptoms synthesized in this study was higher compared to pre-pandemic prevalence in similar populations. Evidently, mental health screening and intervention should be a top priority for universities and colleges during the pandemic.Entities:
Keywords: Anxiety; COVID-19; Depression; Pandemic; Sleep Disturbance; Student; University
Mesh:
Year: 2021 PMID: 33984824 PMCID: PMC9225824 DOI: 10.1016/j.psychres.2021.113863
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 11.225
Fig. 1PRISMA flowchart for the identification and selection of observational studies.
Abbreviations: CINAHL Cumulative Index to Nursing and Allied Health Literature; CNKI Chinese National Knowledge Infrastructure; CQVIP Chongqing VIP Information.
Characteristics of Included Studies
| 2020 Amatori | ( | Italy | Cross-Sectional | 64 | 159 | 58 | 23.0 ± 4.0 | PHQ-9 ≥ 5 | - | - |
| 2020 Aslan | ( | Turkey | Cross-Sectional | 3 | 358 | 42 | 23.0 | PHQ-8 ≥ 10 | GAD-7 ≥ 10 | - |
| 2020 Aylie | ( | Ethiopia | Cross-Sectional | 98 | 314 | 37 | 22.6 ± 2.8 | DASS-21D ≥ 10 | DASS-21A ≥ 8 | - |
| 2020 Benham | ( | USA | Repeated Cross-Sectional | - | 450 (T1), 345 (T2) | 27 | 21.1 ± 4.4 (T1), 22.7 ± 6.0 (T2) | - | - | PSQI > 5 |
| 2020 Biber | ( | USA | Cross-Sectional | 50 | 1640 | 39 | - | - | GAD-7 ≥ 5 | - |
| 2020 Bourion-Bédès | ( | France | Cross-Sectional | - | 3936 | 29 | 21.7 ± 4.0 | - | GAD-7 ≥ 5 | - |
| 2020 Chang | ( | China | Cross-Sectional | 91 | 3881 | 37 | 20 | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Chen | ( | China | Cross-Sectional | 89 | 323489 | 40 | - | PHQ-9 ≥ 10 | - | - |
| 2020 Chi | ( | China | Cross-Sectional | 96 | 2038 | 37 | 20.6 ± 1.9 | PHQ-9 ≥ 10 | SAS ≥ 50 | - |
| 2020 Deng A | ( | China | Cross-Sectional | 99 | 517 | 26 | - | - | SAS ≥ 50 | - |
| 2020 Deng B | ( | China | Cross-Sectional | 96 | 1607 | 65 | - | DASS-21D ≥ 10 | DASS-21A ≥ 7 | - |
| 2020 Dhar | ( | Bangladesh | Cross-Sectional | - | 15543 | 67 | - | - | GAD-7 ≥ 5 | - |
| 2020 Díaz-Jiménez | ( | Spain | Cross-Sectional | 20 | 365 | 10 | 23.2 ± 6.2 | - | DASS-21A ≥ 8 | - |
| 2020 Ding | ( | China | Cross-Sectional | 95 | 3055 | 46 | - | Custom Questionnaire | Custom Questionnaire | - |
| 2020 Dong | ( | China | Cross-Sectional | 97 | 4085 | 23 | 18.9 ± 0.6 | SCL-90 (Depression Domain) ≥ 2 | SCL-90 (Anxiety Domain) ≥ 2 | - |
| 2020 Dratva | ( | Switzerland | Cross-Sectional | 18 | 2223 | 33 | 26.4 ± 5.6 | - | GAD-7 ≥ 10 | - |
| 2020 Du | ( | China, Ireland, Malaysia, Taiwan, South Korea, Netherlands, USA | Cross-Sectional | - | 2254 | 31 | 22.5 ± 5.5 | - | GAD-7 ≥ 10 | PSQI > 5 |
| 2020 Essadek | ( | France | Cross-Sectional | 13 | 8004 | 33 | 21.7 | PHQ-9 ≥ 10 | GAD-7 ≥ 7 | - |
| 2020 Fan A | ( | China | Cross-Sectional | 97 | 4148 | 27 | 20.6 ± 1.5 | - | SAS ≥ 50 | - |
| 2020 Fan B | ( | China | Cross-Sectional | 93 | 932 | 47 | - | - | - | PSQI > 7 |
| 2020 Fan C | ( | China | Longitudinal | - | 406 | - | - | - | SAS ≥ 50 | - |
| 2020 Fawaz | ( | Lebanon | Cross-Sectional | 84 | 520 | 39 | 21.0 ± 2.7 | DASS-21D ≥ 10 | DASS-21A ≥ 8 | - |
| 2020 Feltz-Cornelis | ( | UK | Cross-Sectional | 5 | 925 | 26 | 27.5 | PHQ-9 ≥ 10 | GAD-7 ≥ 10 | - |
| 2020 Fu | ( | China | Cross-Sectional | - | 89588 | 44 | - | - | GAD-7 ≥ 5 | - |
| 2020 Gavurova | ( | Slovakia | Cross-Sectional | 84 | 1523 | 36 | - | PHQ-9 ≥ 5 | - | - |
| 2020 Ge | ( | China | Cross-Sectional | 80 | 2009 | 49 | - | - | GAD-7 ≥ 7 | ISI > 14 |
| 2020 Ghazawy | ( | Egypt | Cross-Sectional | - | 1335 | 38 | - | DASS-21D ≥ 10 | DASS-21A ≥ 8 | - |
| 2020 Graupensperger | ( | USA | Cross-Sectional | 58 | 135 | 37 | 19.8 ± 1.4 | PROMIS-8D T-Score ≥ 55 | - | - |
| 2020 Gritsenko | ( | Russia, Belarus | Cross-Sectional | - | 939 | 19 | 21.8 ± 5.4 | FCV-19S | - | - |
| 2020 Han | ( | China | Cross-Sectional | 93 | 405 | 33 | - | DASS-21D ≥ 10 | DASS-21A ≥ 8 | - |
| 2020 Islam | ( | Bangladesh | Cross-Sectional | 95 | 476 | 67 | - | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Ji | ( | China | Cross-Sectional | 98 | 515 | 24 | - | - | - | PSQI ≥ 8 |
| 2020 Jiang | ( | China | Cross-Sectional | 96 | 472 | 42 | - | - | SCL-90 (Anxiety Domain) ≥ 2 | - |
| 2020 Khoshaim | ( | Saudi Arabia | Cross-Sectional | 8 | 400 | 25 | - | - | SAS ≥ 45 | - |
| 2020 Lai | ( | UK, USA | Cross-Sectional | - | 124 | 36 | - | - | - | ISI ≥ 15 |
| 2020 Li | ( | China | Cross-Sectional | 96 | 1000 | - | 21.8 ± 2.5 | - | SAS ≥ 50 | - |
| 2020 Lian | ( | China | Cross-Sectional | 96 | 1437 | 55 | - | SCL-90 (Depression Domain) ≥ 2 | SCL-90 (Anxiety Domain) ≥ 2 | - |
| 2020 Liang | ( | China | Cross-Sectional | 1 | 4164 | 52 | - | PHQ-9 ≥ 5 | - | - |
| 2020 Lin A | ( | China | Cross-Sectional | - | 625 | 35 | 20.2 ± 1.9 | CES-D ≥ 16 | - | - |
| 2020 Lin B | ( | China | Cross-Sectional | 98 | 1297 | 44 | - | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Liu | ( | China | Cross-Sectional | 96 | 191 | - | - | SCL-90 (Depression Domain) ≥ 2 | SCL-90 (Anxiety Domain) ≥ 2 | - |
| 2020 Ma A | (L. | China | Cross-Sectional | 97 | 516 | 53 | 20.8 ± 1.4 | SCL-90 (Depression Domain) ≥ 2 | SCL-90 (Anxiety Domain) ≥ 2 | - |
| 2020 Ma B | ( | China | Cross-Sectional | 91 | 746217 | 44 | - | PHQ-9 ≥ 7 | GAD-7 ≥ 7 | - |
| 2020 Naser | ( | Jordan | Cross-Sectional | - | 1165 | 46 | - | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Nurunnabi | ( | China | Cross-Sectional | - | 559 | 40 | - | - | Custom Questionnaire | - |
| 2020 Ozamiz-Etxebarria | ( | Spain | Longitudinal | 92 | 44 | 16 | 19.5 | - | GAD-7 ≥ 7 | - |
| 2020 Pavithra | ( | India | Cross-Sectional | - | 396 | 46 | - | - | - | Custom Questionnaire |
| 2020 Perz | ( | USA | Cross-Sectional | - | 237 | 27 | 30.3 ± 10.2 | - | GAD-7 ≥ 5 | - |
| 2020 Qiu | ( | China | Cross-Sectional | 98 | 1100 | 29 | - | - | GAD-7 ≥ 5 | - |
| 2020 Ren | ( | China | Cross-Sectional | - | 4560 | 27 | 21.1 ± 1.4 | SDS ≥ 53 | - | - |
| 2020 Rogowska A | ( | Ukraine | Cross-Sectional | 98 | 1512 | 31 | - | PHQ-9 ≥ 10 | GAD-7 ≥ 10 | - |
| 2020 Rogowska B | ( | Poland | Cross-Sectional | 100 | 914 | 57 | 23.0 ± 2.6 | - | GAD-7 ≥ 10 | - |
| 2020 Rudenstine | ( | USA | Cross-Sectional | 62 | 1821 | 27 | - | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Saddik | ( | UAE | Longitudinal | 93 | 1090 | 28 | 20.5 ± 2.3 | - | GAD-7 ≥ 10 | - |
| 2020 Salman | ( | Pakistan | Cross-Sectional | - | 1134 | 30 | 21.7 ± 3.5 | PHQ-9 ≥ 10 | GAD-7 ≥ 10 | - |
| 2020 Sañudo | ( | Spain | Cross-Sectional | 14 | 20 | 55 | 22.6 ± 3.4 | - | - | PSQI > 5 |
| 2020 Sayeed | ( | Bangladesh | Cross-Sectional | - | 589 | 66 | - | DASS-21D ≥ 10 | DASS-21A ≥ 7 | - |
| 2020 Scotta | ( | Argentina | Cross-Sectional | - | 584 | 18 | 22.5 ± 6.3 | - | - | ISI ≥ 15 |
| 2020 Sundarasen | ( | Malaysia | Cross-Sectional | 93 | 983 | 34 | - | - | SAS ≥ 45 | - |
| 2020 Tang | ( | China | Cross-Sectional | 69 | 2485 | 39 | 19.8 ± 1.6 | PHQ-9 ≥ 10 | - | - |
| 2020 Tasnim | ( | Bangladesh | Cross-Sectional | 98 | 3331 | 59 | 21.4 ± 1.9 | DASS-21D > 14 | DASS-21A > 10 | Custom Questionnaire |
| 2020 Thahir | ( | Indonesia | Cross-Sectional | - | 1044 | 17 | 21.1 ± 2.4 | KADS-6 ≥ 6 | - | - |
| 2020 Verma | ( | India | Cross-Sectional | - | 131 | 48 | - | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Wang A | ( | China | Cross-Sectional | 100 | 3178 | 28 | - | - | HAM-A ≥ 7 | - |
| 2020 Wang B | ( | China | Cross-Sectional | 95 | 3611 | 40 | - | - | SAS ≥ 50 | - |
| 2020 Wang C | ( | China | Cross-Sectional | 80 | 44447 | 45 | 21.0 ± 2.4 | CES-D ≥ 28 | SAS ≥ 50 | - |
| 2020 Wang D | (S. | China | Cross-Sectional | - | 1365 | 40 | - | - | SAS ≥ 50 | - |
| 2020 Wang E | ( | China | Cross-Sectional | - | 3092 | 34 | - | - | GAD-7 ≥ 5 | SRSS ≥ 23 |
| 2020 Wang F | (C. | China | Longitudinal | 31 | 1172 | 39 | - | - | SAS ≥ 50 | - |
| 2020 Wang G | (Y. | China | Cross-Sectional | 89 | 3179 | 30 | - | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Wathelet | ( | France | Cross-Sectional | 4 | 69054 | 28 | - | BID-13 ≥ 16 | STAI ≥ 56 | - |
| 2020 Wu A | (B. B. | China | Cross-Sectional | 95 | 807 | 51 | - | SCL-90 (Depression Domain) ≥ 2 | SCL-90 (Anxiety Domain) ≥ 2 | - |
| 2020 Wu B | ( | China | Cross-Sectional | - | 11787 | 43 | 20.5 ± 1.8 | - | GAD-7 ≥ 5 | - |
| 2020 Xia | ( | China | Cross-Sectional | 100 | 1186 | 17 | - | - | EAS ≥ 40 | - |
| 2020 Xiang | ( | China | Cross-Sectional | 60 | 1396 | 63 | 20.7 ± 1.8 | SDS ≥ 50 | SAS ≥ 50 | - |
| 2020 Xiao | ( | China | Cross-Sectional | 100 | 3966 | 40 | - | PHQ-9 ≥ 5 | - | - |
| 2020 Xu | ( | China | Cross-Sectional | 97 | 6891 | 31 | - | SDS ≥ 53 | SAS ≥ 50 | - |
| 2020 Yang A | ( | China | Cross-Sectional | 93 | 1667 | 48 | 20.6 ± 2.0 | PQEEPH | PQEEPH | - |
| 2020 Yang B | (X. J. | China | Cross-Sectional | 94 | 4139 | 35 | - | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Ye | ( | China | Cross-Sectional | 96 | 5532 | 56 | - | Custom Questionnaire | Custom Questionnaire | Custom Questionnaire |
| 2020 Yi | ( | China | Cross-Sectional | 91 | 393 | 31 | 21.7 ± 0.9 | SDS ≥ 53 | SAS ≥ 50 | - |
| 2020 Yue | ( | China | Cross-Sectional | 100 | 737 | 29 | - | - | Custom Questionnaire | - |
| 2020 Zhang A | (Y. | China | Longitudinal | 100 | 66 | 38 | 20.7 ± 2.1 | DASS-21D ≥ 10 | DASS-21A ≥ 8 | PSQI > 5 |
| 2020 Zhang B | (L. L. | China | Cross-Sectional | - | 7833 | 27 | 19.8 ± 1.9 | PHQ-9 ≥ 5 | GAD-7 ≥ 5 | - |
| 2020 Zhang C | (X. Y. | China | Cross-Sectional | 97 | 1409 | 52 | - | SDS ≥ 53 | SAS ≥ 50 | - |
| 2020 Zhang D | (B. | China | Repeated Cross-Sectional | 99 (T1), 98 (T2) | 2504 (T1), 2647 (T2) | 27 | - | - | Custom Questionnaire | Custom Questionnaire |
| 2020 Zhang E | (J. | China | Cross-Sectional | 91 | 312 | 21 | 19.6 ± 2.0 | PHQ-9 ≥ 5 | - | - |
| 2020 Zhao A | ( | China | Cross-Sectional | - | 376 | 19 | - | Custom Questionnaire | Custom Questionnaire | - |
| 2020 Zhao B | ( | Korea, China, Japan | Cross-Sectional | 99 | 821 | 37 | 23.1 ± 4.8 | PHQ-9 ≥ 5 | - | - |
Cells containing “-“ indicate that the study author did not provide any relevant information for that column.
Abbreviations: USA United States of America, UAE United Arab Emirates, UK United Kingdom, SD standard deviation, PHQ-9 Patient Health Questionnaire-9, GAD-7 General Anxiety Disorder 7-item scale, SAS Zung Self-Rating Anxiety Scale, DASS-21D Depression Anxiety Stress Scales depression subscale, DASS-21A Depression Anxiety Stress Scales anxiety subscale, PSQI Pittsburgh Sleep Quality Index, ISI Insomnia Severity Index, PROMIS-8D Patient-Reported Outcomes Measurement Information System Depression-8, FCV-19S Fear of COVID-19 Scale, SCL-90 Symptom Checklist-90, HAM-A Hamilton Anxiety Rating Scale, CES-D Center for Epidemiologic Studies Depression Scale, EAS Existence of Anxiety Scale, PQEEPH Psychological Questionnaires for Emergent Events of Public Health, SRSS Self-Rating Scale of Sleep, KADS Kutcher Adolescent Depression Scale, BID-13 13-item Beck Depression Inventory, STAI State-Trait Anxiety Inventory, PHQ-8 Patient Health Questionnaire-8.
The interquartile range was 19-22.
The median age was 26.2 with a range of 18-77.
The age range was 18-28.
The median age was 20.0 with an interquartile range of 18-22.
Quality ratings of included studies using the modified Newcastle-Ottawa Scale
| 2020 Amatori | * | * | 2 | |||
| 2020 Aslan | * | * | * | 3 | ||
| 2020 Aylie | * | * | * | * | * | 5 |
| 2020 Benham | * | * | 2 | |||
| 2020 Biber | * | * | 2 | |||
| 2020 Bourion-Bédès | * | * | 2 | |||
| 2020 Chang | * | * | * | 3 | ||
| 2020 Chen | * | * | * | 3 | ||
| 2020 Chi | * | * | * | 3 | ||
| 2020 Deng A | * | * | * | 3 | ||
| 2020 Deng B | * | * | * | 3 | ||
| 2020 Dhar | * | * | * | 3 | ||
| 2020 Díaz-Jiménez | * | * | 2 | |||
| 2020 Ding | * | * | * | 3 | ||
| 2020 Dong | * | * | * | 3 | ||
| 2020 Dratva | * | * | * | 3 | ||
| 2020 Du | * | * | 2 | |||
| 2020 Essadek | * | * | * | * | 4 | |
| 2020 Fan A | * | * | 2 | |||
| 2020 Fan B | * | * | 2 | |||
| 2020 Fan C | * | * | * | 3 | ||
| 2020 Fawaz | * | * | * | 3 | ||
| 2020 Feltz-Cornelis | * | * | * | 3 | ||
| 2020 Fu | * | * | 2 | |||
| 2020 Gavurova | * | * | * | 3 | ||
| 2020 Ge | * | * | * | 3 | ||
| 2020 Ghazawy | * | * | 2 | |||
| 2020 Graupensperger | * | * | * | * | 4 | |
| 2020 Gritsenko | * | * | * | 3 | ||
| 2020 Han | * | * | * | 3 | ||
| 2020 Islam | * | * | * | 3 | ||
| 2020 Ji | * | * | * | 3 | ||
| 2020 Jiang | * | * | * | 3 | ||
| 2020 Khoshaim | * | * | * | 3 | ||
| 2020 Lai | * | * | 2 | |||
| 2020 Li | * | * | * | * | 4 | |
| 2020 Lian | * | * | * | * | 4 | |
| 2020 Liang | * | * | 2 | |||
| 2020 Lin A | * | * | 2 | |||
| 2020 Lin B | * | * | * | 3 | ||
| 2020 Liu | * | * | 2 | |||
| 2020 Ma A | * | * | * | 3 | ||
| 2020 Ma B | * | * | * | * | 4 | |
| 2020 Naser | * | * | 2 | |||
| 2020 Nurunnabi | * | * | 2 | |||
| 2020 Ozamiz-Etxebarria | * | * | * | 3 | ||
| 2020 Pavithra | * | 1 | ||||
| 2020 Perz | * | * | 2 | |||
| 2020 Qiu | * | * | * | * | 4 | |
| 2020 Ren | * | * | * | 3 | ||
| 2020 Rogowska A | * | * | * | 3 | ||
| 2020 Rogowska B | * | * | * | 3 | ||
| 2020 Rudenstine | * | * | * | 3 | ||
| 2020 Saddik | * | * | * | * | 4 | |
| 2020 Salman | * | * | 2 | |||
| 2020 Sanudo | * | * | * | 3 | ||
| 2020 Sayeed | * | * | * | 3 | ||
| 2020 Scotta | * | * | 2 | |||
| 2020 Sundarasen | * | 1 | ||||
| 2020 Tang | * | * | * | 3 | ||
| 2020 Tasnim | * | * | 2 | |||
| 2020 Thahir | * | * | 2 | |||
| 2020 Verma | * | * | * | 3 | ||
| 2020 Wang A | * | * | 2 | |||
| 2020 Wang B | * | * | * | 3 | ||
| 2020 Wang C | * | * | * | 3 | ||
| 2020 Wang D | * | * | 2 | |||
| 2020 Wang E | * | * | 2 | |||
| 2020 Wang F | * | * | 2 | |||
| 2020 Wang G | * | * | * | 3 | ||
| 2020 Wathelet | * | * | 2 | |||
| 2020 Wu A | * | * | * | * | 4 | |
| 2020 Wu B | * | * | * | 3 | ||
| 2020 Xia | * | * | 2 | |||
| 2020 Xiang | * | * | 2 | |||
| 2020 Xiao | * | * | 2 | |||
| 2020 Xu | * | * | * | * | 4 | |
| 2020 Yang A | * | * | * | 3 | ||
| 2020 Yang B | * | * | * | 3 | ||
| 2020 Ye | * | * | * | 3 | ||
| 2020 Yi | * | * | 2 | |||
| 2020 Yue | * | * | 2 | |||
| 2020 Zhang A | * | * | * | * | 4 | |
| 2020 Zhang B | * | * | * | 3 | ||
| 2020 Zhang C | * | * | * | * | 4 | |
| 2020 Zhang D | * | * | * | 3 | ||
| 2020 Zhang E | * | * | * | 3 | ||
| 2020 Zhao A | * | * | * | 3 | ||
| 2020 Zhao B | * | * | * | 3 |
Subgroup Analysis of Depression, Anxiety, and Sleep Disturbance Prevalence
| 41%, 95% CI: 27-55% | 37%, 95% CI: 21-53% | 19%, 95% CI: 12-27% | ||
| 48%, 95% CI: 35-62% | 44%, 95% CI: 34-55% | 20%, 95% CI: 15-26% | ||
| 61%, 95% CI: 40-79% | 49%, 95% CI: 25-73% | |||
| 49%, 95% CI: 39-60% | 40%, 95% CI: 14-70% | |||
| 52%, 95% CI: 28-76% | 61%, 95% CI: 20-95% | |||
| 47%, 95% CI: 18-78% | 44%, 95% CI: 15-77% | |||
| - | 6%, 95% CI: 2-11% | - | ||
| 32%, 95% CI: 22-44% | 24%, 95% CI: 17-30% | 30%, 95% CI: 18-44% | ||
| 25%, 95% CI: 0-73% | 14%, 95% CI: 4-29% | 20%, 95% CI 16-24% | ||
| 17%, 95% CI: 8-27% | 19%, 95% CI: 12-27% | - | ||
| 21%, 95% CI: 9-35% | 19%, 95% CI: 11-29% | - | ||
| 24%, 95% CI: 12-38% | 22%, 95% CI: 13-33% | - | ||
| 29%, 95% CI: 15-45% | 25%, 95% CI: 14-37% | - | ||
| 23%, 95% CI: 21-26% | 20%, 95% CI: 15-25% | - | ||
| 13%, 95% CI: 8-19% | 11%, 95% CI: 6-18% | - | ||
| 8%, 95% CI: 5-12% | 6%, 95% CI: 3-12% | - | ||
| 24%, 95% CI: 20-28% | 23%, 95% CI: 18-28% | 23%, 95% CI: 14-32% | ||
| 70%, 95% CI: 58-80% | 73%, 95% CI: 31-99% | 27%, 95% CI: 26-29% | ||
| 29%, 95% CI: 7-57% | 42%, 95% CI: 26-60% | - | ||
| 55%, 95% CI: 8-97% | 74%, 95% CI: 46-94% | 66%, 95% CI: 62-69% | ||
| 53%, 95% CI: 49-57% | - | - | ||
| 42%, 95% CI: 36-48% | - | - | ||
| 87%, 95% CI: 85-89% | 80%, 95% CI: 77-82% | - | ||
| - | 56%, 95% CI: 39-72% | 45%, 95% CI: 24-67% | ||
| - | 23%, 95% CI: 20-25% | - | ||
| 45%, 95% CI: 42-48% | 34%, 95% CI: 31-37% | - | ||
| - | 8%, 95% CI: 6-10% | - | ||
| 39%, 95% CI: 31-47% | 31%, 95% CI: 24-40% | 65%, 95% CI: 60-70% | ||
| 49%, 95% CI: 44-54% | - | - | ||
| 60%, 95% CI: 52-68% | - | - | ||
| 70%, 95% CI: 68-73% | 54%, 95% CI: 51-56% | - | ||
| 22%, 95% CI: 18-27% | 28%, 95% CI: 23-33% | - | ||
| 31%, 95% CI: 28-34% | - | - | ||
| 77%, 95% CI: 70-83% | - | - | ||
| 33%, 95% CI: 29-38% | 44%, 95% CI: 40-48% | - | ||
| 72%, 95% CI: 69-74% | - | - | ||
| 63%, 95% CI: 58-68% | 52%, 95% CI: 46-57% | - | ||
| 46%, 95% CI: 43-50% | 37%, 95% CI: 34-40% | - | ||
| 32%, 95% CI: 29-34% | 24%, 95% CI: 22-26% | - | ||
| - | 35%, 95% CI: 32-38% | - | ||
| - | 34%, 95% CI: 30-39% | - | ||
| - | 23%, 95% CI: 21-25% | - | ||
| - | - | 27%, 95% CI: 23-31% | ||
Cells containing “-“ indicate that no relevant subgroup analyses had been conducted.
Abbreviations: CI Confidence Interval, USA United States of America, UAE United Arab Emirates, UK United Kingdom
Only one study was included in this subgroup.
Fig. 2Forest plot for the pooling of depression prevalence. Studies were separated into subgroups based on the screening tool and cutoff values used for evaluating depression. The differences between subgroups were statistically significant (P<0.01).
Abbreviations: CI Confidence Interval; PHQ-9 Patient Health Questionnaire-9; DASS-21D Depression Anxiety Stress Scales, depression subscale; SCL-90 Symptom Checklist-90; SDS Zung Self-Rating Depression Scale; CES-D Center for Epidemiologic Studies Depression Scale; FCV-19S Fear of COVID-19 Scale; PQEEPH Psychological Questionnaires for Emergent Events of Public Health; PROMIS-8D Patient-Reported Outcomes Measurement Information System Depression-8, BID-13 13-item Beck Depression Inventory, KADS Kutcher Adolescent Depression Scale, PHQ-8 Patient Health Questionnaire-8
Fig. 4Forest plot for the pooling of sleep disturbances prevalence. Studies were separated into subgroups based on the screening tool and cutoff values used for evaluating sleep disturbances. The differences between subgroups were statistically significant (P<0.01).
Abbreviations: CI Confidence Interval; PSQI Pittsburgh Sleep Quality Index; ISI Insomnia Severity Index, SRSS Self-Rating Scale of Sleep.
Citation of Included Studies
| Primary Meta-Analysis | ( | ( | ( |
| Gender | ( | ( | ( |
| Financial Difficulties | ( | ( | ( |
| Living Alone | ( | ( | - |
| Education Level | ( | ( | ( |
| Undergraduate Year of Study | ( | ( | ( |
| Severity | ( | ( | - |
| ( | |||
| ( | |||
Cells containing “-“ indicate that no relevant subgroup analyses had been conducted.
Abbreviations: NOS Modified Newcastle-Ottawa Scale
Fig. 3Forest plot for the pooling of anxiety prevalence. Studies were separated into subgroups based on the screening tool and cutoff values used for evaluating anxiety. The differences between subgroups were statistically significant (P<0.01).
Abbreviations: CI Confidence Interval; GAD-7 General Anxiety Disorder 7-item scale; SAS Zung Self-Rating Anxiety Scale; SCL-90 Symptom Checklist-90; DASS-21A Depression Anxiety Stress Scales, anxiety subscale; EAS Existence of Anxiety Scale; HAM-A Hamilton Anxiety Rating Scale; PQEEPH Psychological Questionnaires for Emergent Events of Public Health, STAI State-Trait Anxiety Inventory.